| Literature DB >> 29118328 |
Li Wei1, Jianguang Zhao2, Wei Wu1, Yu Zhang3, Xuyan Fu1, Lifeng Chen3, Xiaoting Wang4.
Abstract
Herpes zoster (HZ) is an infectious dermatosis with high incidence worldwide. Age is a key risk factor for HZ, and postherpetic neuralgia (PHN) is the main sequelae. Until now, no index has been available to predict the pathogenesis of PHN, and rare reports have focused on the immune response during aging and PHN. In this study, we selected immunoglobulin and complement proteins as markers for humoral immunity, while T lymphocyte subsets and natural killer (NK) cells were selected as markers for cell immunity, to systematically study the characteristics of immune responses in the peripheral blood of HZ patients. Our data showed that the absolute number of CD3+ T cells and CD8+ T cells decreased during aging and PHN. This implies that more attention should be paid to prevent the occurrence of PHN, especially in the aged population.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29118328 PMCID: PMC5678144 DOI: 10.1038/s41598-017-15390-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographics of participants.
| Variables of interest | Herpes-zoster group(n = 192) | Control group(n = 28) | Old Herpes-zoster group(n = 27) | Control group(n = 14) |
|---|---|---|---|---|
| Age (years), (mean ± S.D.) | 57.69 ± 14.39 | 55.75 ± 9.78 | 67.74 ± 7.43 | 57.29 ± 5.08 |
| Sex (% female) | 48.96 | 53.57 | 44.44 | 42.86 |
| CRP(mg/l) | 11.43 ± 0.96▲▲ | 0.45 ± 0.05 | 14.91 ± 9.63▲▲ | 0.46 ± 0. 29 |
| WBC(109/l) | 5.66 ± 0.16 | 5.49 ± 0.31 | 6.28 ± 2.38 | 6.46 ± 2.22 |
| Neutrophil (%) | 60.81 ± 0.86 | 58.76 ± 1.02 | 62.88 ± 13.52 | 59.83 ± 15.68 |
| Neutrophil(109/l) | 3.59 ± 0.13▲▲ | 3.01 ± 0.16 | 4.34 ± 2.27 | 4.10 ± 2.19 |
| Lymphocyte (%) | 26.46 ± 0.78▲▲ | 30.61 ± 1.05 | 24.90 ± 10.03 | 27.15 ± 11.79 |
| Lymphocyte(109/l) | 1.54 ± 0.08 | 1.56 ± 0.13 | 1.45 ± 0.50 | 1.59 ± 0.50 |
| Monocyte (%) | 10.47 ± 0.32▲▲ | 8.09 ± 0.28 | 10.47 ± 4.96 | 11.46 ± 5.79 |
| Monocyte(109/l) | 0.59 ± 0.02 | 0.70 ± 0.11 | 0.62 ± 0.26 | 0.72 ± 0.26 |
| History of Herpes-zoster (whether they had been diagnosed at a medical institution) | no | no | no | no |
| History of Cytomegalovirus (whether they had been diagnosed at a medical institution) | no | no | no | no |
| History of Epstein Barr virus (whether they had been diagnosed at a medical institution) | no | no | no | no |
| History of Herpes simplex virus (whether they had been diagnosed at a medical institution) | no | no | no | no |
| Seroprevalence of Cytomegalovirus (%total group) | 55.21 | 53.57 | 56.37 | 54.37 |
| Seroprevalence of Epstein Barr virus (%total group) | 45.83 | 64.29 | 59.52 | 55.63 |
| Seroprevalence of Herpes Simplex virus 1 (%total group) | 39.06 | 35.71 | 44.44 | 42.86 |
| Seroprevalence of Herpes Simplex virus 2 (%total group) | 11.46 | 10.71 | 14.81 | 14.29 |
| Disease duration (days) | 3.02 ± 1.26 | NA | 2.86 ± 1.17 | NA |
| Postherpetic neuralgia (% at 4 weeks) | 46.35 | NA | 50.00 | NA |
NA: not applicable.
▲▲compare with the Control group P < 0.01.
Figure 1Gating strategy of T lymphocyte subsets and NK cells.
Figure 2Gating strategy of different phenotypes of CD8 T cells.
Absolute numbers of T lymphocyte subsets and NK cells in the herpes zoster group and control group.
| Groups | CD3+ T cells (109/l) | CD4+ T cells (109/l) | CD8+ T cells (109/l) | NK cells (109/l) |
|---|---|---|---|---|
| Group 1 (n = 192) | 0.69 ± 0.04 | 0.33 ± 0.02 | 0.31 ± 0.02 | 0.23 ± 0.01 |
| Group 2 (n = 28) | 1.17 ± 0.10 | 0.59 ± 0.06 | 0.51 ± 0.04 | 0.23 ± 0.03 |
| t value | −4.06 | −4.49 | −3.28 | 0.06 |
| p value | 0.00 | 0.00 | 0.00 | 0.96 |
Group 1: Herpes zoster group; Group 2: Control group.
Figure 3Absolute numbers of T lymphocyte subsets and NK cells in different age groups with herpes zoster.
Serum immunoglobulin and complement proteins in the herpes zoster group and control group.
| Groups | IgG (mg/dl) | IgA (mg/dl) | IgM (mg/dl) | C3 (mg/dl) | C4 (mg/dl) |
|---|---|---|---|---|---|
| Group 1 (n = 192) | 1225.48 ± 399.24 | 232.76 ± 114.58 | 120.14 ± 72.01 | 78.68 ± 44.98 | 54.22 ± 44.01 |
| Group 2 (n = 28) | 1206.50 ± 288.44 | 241.77 ± 117.51 | 105.53 ± 57.55 | 80.81 ± 40.82 | 46.82 ± 36.11 |
| t value | 0.31 | −0.38 | 1.21 | −0.25 | 0.98 |
| p value | 0.76 | 0.71 | 0.23 | 0.80 | 0.33 |
Group 1: Herpes zoster group; Group 2: Control group.
Serum immunoglobulin, complement proteins and plasma CRP levels in different age groups with herpes zoster.
| Groups | IgG (mg/dl) | IgA (mg/dl) | IgM (mg/dl) | C3 (mg/dl) | C4 (mg/dl) | CRP (mg/l) |
|---|---|---|---|---|---|---|
| Group 1 (n = 25) | 1076.32 ± 449.20 | 203.56 ± 111.81 | 115.62 ± 68.85 | 67.36 ± 54.56 | 63.92 ± 44.24 | 9.03 ± 2.00 |
| Group 2 (n = 82) | 1234.04 ± 429.42 | 232.39 ± 122.89 | 122.33 ± 73.42 | 83.34 ± 44.05 | 53.93 ± 44.71 | 10.93 ± 1.47 |
| Group 3 (n = 85) | 1260.99 ± 344.52 | 241.72 ± 106.58 | 119.34 ± 72.28 | 77.45 ± 42.64 | 51.65 ± 43.37 | 12.63 ± 1.53 |
Group 1: The young group;
Group 2: The middle age group;
Group 3: The old age group.
Serum immunoglobulin, complement proteins and plasma CRP in the postherpetic and non-postherpetic neuralgia group.
| Groups | IgG (mg/dl) | IgA (mg/dl) | IgM (mg/dl) | C3 (mg/dl) | C4 (mg/dl) | CRP (mg/l) |
|---|---|---|---|---|---|---|
| Group 1 (n = 103) | 1224.02 ± 434.91 | 232.59 ± 122.47 | 126.71 ± 77.57 | 73.00 ± 44.84 | 57.43 ± 44.31 | 11.45 ± 1.21 |
| Group 2 (n = 89) | 1227.18 ± 355.31 | 232.97 ± 105.30 | 112.47 ± 64.50 | 85.32 ± 44.47 | 50.47 ± 43.60 | 10.59 ± 1.17 |
| t value | −0.06 | −0.02 | 1.37 | −1.91 | 1.10 | 0.51 |
| p value | 0.96 | 0.98 | 0.17 | 0.06 | 0.28 | 0.61 |
Group 1: non-postherpetic neuralgia group;
Group 2: postherpetic neuralgia group.
Figure 4Absolute numbers of T lymphocyte subsets and NK cells of PHN patients and non-PHN patients in three age groups.
Multivariate analyses the correlations of age and immune markers with PHN.
| PHN | Age | CD3 | CD4 | CD8 | NK | CRP | Neutrophil | Lymphocyte | Monocyte | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||||
|
| 1.00 | 0.21 | −0.02 | 0.01 | −0.15 | 0.09 | −0.05 | −0.10 | −0.04 | 0.07 | |
|
| 0.00 | 0.81 | 0.87 | 0.04 | 0.23 | 0.49 | 0.16 | 0.55 | 0.35 | ||
|
|
| ||||||||||
|
| 0.21 | 1.00 | −0.32 | −0.16 | −0.45 | −0.08 | 0.07 | −0.14 | 0.00 | −0.07 | |
|
| 0.00 | 0.00 | 0.02 | 0.00 | 0.25 | 0.34 | 0.05 | 0.97 | 0.35 | ||
Figure 5Absolute numbers of different phenotypes of CD8 T cells in PHN patients and non-PHN patients for old age HZ patients and controls.